Carbon Or Halogen Bonded Directly At The 2-, 4- Or 5-position Patents (Class 552/652)
  • Patent number: 11780875
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: October 10, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20110313170
    Abstract: This disclosure relates to reagents and methods useful in the synthesis of aryl fluorides, for example, in the preparation of 18F labeled radiotracers. The reagents and methods provided herein may be used to access a broad range of compounds, including aromatic compounds, heteroaromatic compounds, amino acids, nucleotides, and synthetic compounds.
    Type: Application
    Filed: June 30, 2011
    Publication date: December 22, 2011
    Inventor: Stephen Gregory DiMagno
  • Patent number: 6046186
    Abstract: Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have the structural formula (I) wherein r1 is an optional double bond, R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen and lower alky, or together form a cyclic substituent (II) ##STR1## wherein Q is NH, O or CH.sub.2, and the other various substituents are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat estrogen-dependent disorders are provided as well.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: April 4, 2000
    Assignee: SRI International
    Inventors: Masato Tanabe, Richard H. Peters, Wan-Ru Chao, Kazuhiko Shigeno
  • Patent number: 5892069
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: April 6, 1999
    Assignee: The Children's Medical Center Corporation
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Patent number: 5804576
    Abstract: Steroids of the formula: ##STR1## useful as cancer preventive agents, anti-obesity agents, anti-hyperglycemic agents, anti-aging agents, and anti-hypercholesterolemic agents and anti-auto-immune agents.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 8, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Arthur G. Schwartz, John R. Williams, Magid Abou-Gharbia, Ann R. Swern, Marvin Louis Lewbart
  • Patent number: 5723455
    Abstract: Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat androgen-related clinical conditions are provided, as are methods and compositions for using the compounds as contraceptive agents.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: March 3, 1998
    Assignee: SRI International
    Inventors: Masato Tanabe, Wan-Ru Chao, Wesley K. M. Chong, David F. Crowe
  • Patent number: 5714481
    Abstract: Steroids of the formula: ##STR1## useful as cancer preventive agents, anti-obesity agents, anti-hyperglycemic agents, anti-aging agents, and anti-hypercholesterolemic agents and anti-auto-immune agents.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: February 3, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Arthur G. Schwartz, John R. Williams, Magid Abou-Gharbia, Daniel Swern, deceased, Marvin Louis Lewbart
  • Patent number: 5206229
    Type: Grant
    Filed: October 10, 1990
    Date of Patent: April 27, 1993
    Assignee: Leo Pharmaceutical Products LTD
    Inventors: Martin J. Calverley, Lise Binderup, Ernst T. Binderup
  • Patent number: 5157031
    Type: Grant
    Filed: March 21, 1989
    Date of Patent: October 20, 1992
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Arthur G. Schwartz, Marvin L. Lewbart
  • Patent number: 4966897
    Abstract: This invention is directed to 4-substituted 17.beta.-(cyclopropyloxy)androst-5-en-3.beta.-ols and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The ethers are prepared by using the Simmons-Smith reaction and an appropriate vinyl ether.
    Type: Grant
    Filed: August 15, 1989
    Date of Patent: October 30, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael R. Angelastro, Thomas R. Blohm